NLS Pharmaceutics to present new preclinical data on Mazindol ER at ASCP

NLS Pharmaceutics (NLSP) announces that it will present new preclinical data on Mazindol ER at the 2025 Annual Meeting of the American Society of Clinical Psychopharmacology, or ASCP. ASCP Annual Meeting will be held at the Fairmont Scottsdale Princess in Scottsdale, Arizona in May 27-30. NLS intends to present its poster titled, ‘Evaluating the Effects of Mazindol on Fentanyl Reward and Dependence in C57BL/6J Mice and Sprague-Dawley Rats during the poster session on May 29. The preclinical study to be featured in the poster was conducted by Key-Obs SAS in collaboration with NLS and other European academic institutions. The study results demonstrate that Mazindol significantly reduced both the rewarding effects of fentanyl and the severity of its withdrawal symptoms in validated rodent models. Highlights from Study KO-943 include: In C57BL/6J mice, Mazindol at 0.5 mg/kg significantly reduced fentanyl-induced conditioned place preference, effectively neutralizing the behavioral reward effects typically observed with fentanyl exposure. Sprague-Dawley rats, Mazindol administered at 0.5 and 1.0 mg/kg dose-dependently reduced fentanyl withdrawal symptoms, including agitation, salivation, and motor disturbances, as measured by the Gellert-Holtzman scale. While standard stimulant and non-stimulant medications approved for ADHD have shown no significant efficacy in addressing opioid withdrawal or reward, Mazindol’s ability to reduce both in fentanyl-exposed animals suggests it may offer advantages over conventional treatments. This aligns with clinical observations that differentiate the pharmacodynamic profile of Mazindol from traditional monoaminergic agents, as discussed in comparative studies such as Wigal, CNS Drugs.